LVZPF OTC
Livzon Pharmaceutical Group Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: +86.4%
5Y: +66.2%
$5.22
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$3.1B
+4.0% ▲
5Y CAGR: +7.5%
Capital Expenditures
$559M
+1.9% ▲
5Y CAGR: -2.9%
Free Cash Flow
$2.5B
+5.4% ▲
5Y CAGR: +10.9%
Dividends Paid
$957M
+28.6% ▲
Buybacks
$565M
+34.2% ▲
Net Change in Cash
-$1.1B
-567.2% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $2.0B | $2.0B | $1.9B | $2.3B | $2.0B |
| Depreciation & Amort. | $445M | $652M | $840M | $575M | $539M |
| Stock-Based Comp. | $33M | $47M | $0 | $0 | $0 |
| Change in Working Capital | -$653M | -$122M | $3M | -$185M | $59M |
| Other Non-Cash Items | $110M | $237M | $653M | $284M | $597M |
| Operating Cash Flow | $1.9B | $2.8B | $3.4B | $3.0B | $3.1B |
| — Investing Activities — | |||||
| Capital Expenditures | -$1.3B | -$940M | -$820M | -$570M | -$559M |
| Acquisitions (Net) | $3M | $3M | $69M | $0 | $30M |
| Investment Purchases | -$786M | -$399M | -$473M | -$794M | -$8.7B |
| Investment Sales | $209M | $131M | $472M | $707M | $7.4B |
| Other Investing | $6M | -$24M | -$24M | -$3M | -$1.8B |
| Investing Cash Flow | -$1.9B | -$1.2B | -$777M | -$660M | -$3.7B |
| — Financing Activities — | |||||
| Net Debt Issuance | $766M | $886M | $532M | -$162M | -$905M |
| Stock Repurchased | -$238M | -$56M | -$346M | -$859M | -$565M |
| Dividends Paid | -$1.2B | -$1.2B | -$1.5B | -$1.3B | -$957M |
| Other Financing | -$175M | -$250M | -$778M | -$125M | -$196M |
| Financing Cash Flow | -$815M | -$720M | -$1.7B | -$2.5B | -$2.6B |
| Net Change in Cash | -$827M | $947M | $904M | -$159M | -$1.1B |
| Cash End of Period | $9.1B | $10.1B | $11.0B | $10.8B | $9.3B |
| Free Cash Flow | $593M | $1.8B | $2.4B | $2.4B | $2.5B |